August 20, 2024 Sarcoma Centers Registry Continues to Grow SARC’s Sarcoma Centers Registry is well underway with 77 institutions and counting on the map! Read more
Research Advocacy Council News and Upcoming Events The Research Advocacy Council will have their quarterly meeting on September 9, 2024. Read more
SARC 044 Open for Enrollment SARC’s newest clinical trial, SARC044, is now open for enrollment! This trial aims to enroll patients with GIST who have previously progressed on sunitinib. Read more
SMTB Excited to Announce DDLPS Webcast Event with PeerView SARC’s SMTB and PeerView are collaborating on an upcoming educational webcast on dedifferentiated liposarcoma (DDLPS) on Friday, October 11, 2024 from 12 pm-1 pm CDT. Read more
June 17, 2024 Research Advocacy Council (RAC) Updates The Research Advocacy Council is working on several projects behind the scenes, including involvement in the newest SARC clinical trial, SARC044. Read more
June 13, 2024 SARC037 Progress Announced at ASCO 2024 Dr. Patrick Grohar presented the SARC037 findings at ASCO 2024. The results suggest that EWS::FLI1 is a target for Ewing sarcoma and the combination of trabectedin/irinotecan is active in treatment-refractory Ewing sarcoma patients. Read more
SARC Sarcoma Centers Registry Accepting Applications We are pleased to announce that SARC’s new, global Sarcoma Centers Registry, is live. We are still requesting that interested sarcoma centers submit a brief application form. Read more
SARC Multidisciplinary Tumor Board (SMTB) Updates SARC Multidisciplinary Tumor Board meets the second Friday of every month at 1:00 p.m. ET. Each case that has been presented has provided captivating dialogue. Click to learn more about our recent cases. Read more
June 10, 2024 Sarcoma Centers Spotlight In this SARC Sarcoma Centers Spotlight we feature Jessica Lowenstein, M.S., DABR, a medical physicist, and Hannah Nguyen, M.S. (RS), CMD, a medical dosimetrist, both of whom work at RQA Lab and IROC Houston located at MD Anderson Cancer Center. Read more
June 7, 2024 SU2C-SARC032 Positive Results Revealed at ASCO Dr. David Kirsch unveiled the SU2C-SARC032 findings at ASCO 2024. The results indicate that adding pembro decreases the risk of cancer recurrence by 43% two years after treatment. Read more